Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Revenue of Allogene Therapeutics, Inc. (ALLO)
Revenue in 2023 (TTM): $95 K
According to Allogene Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $95 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Allogene Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $95 K | $-242,819,000 | $-287,048,000 | $-327,265,000 | $-327,265,000 |
| 2022 | $243 K | $-16,485,000 | $-335,449,000 | $-332,632,000 | $-329,815,000 |
| 2021 | $38.49 M | $25.42 M | $-255,792,000 | $-257,005,000 | $-244,837,000 |
| 2020 | $ | $-11,541,000 | $-258,243,000 | $-250,221,000 | $-233,471,000 |
| 2019 | $ | $-5,027,000 | $-184,925,000 | $-184,925,000 | $-184,594,000 |
| 2018 | $ | $-1,500,000 | $-208,264,000 | $-211,622,000 | $-211,505,000 |
| 2017 | $ | $ | $-2,000 | $-2,000 | $-2,000 |